ARTICLE | Company News
Terns acquires NASH compounds from Eli Lilly
April 6, 2018 8:49 PM UTC
Terns Pharmaceuticals Inc. (San Mateo, Calif.) gained exclusive, worldwide rights to develop and commercialize three small molecule non-alcoholic steatohepatitis candidates from Eli Lilly and Co. (NYSE:LLY). The partners declined to disclose financial terms.
Terns will initially focus on developing the candidates in China...